1Department of Chemistry, University of Zanjan, Zanjan, Iran
2Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Objective(s): Gallium-68 DOTA-DPhe1-Tyr3-Octreotide (68Ga-DOTATOC) has been applied by several European centers for the treatment of a variety of human malignancies. Nevertheless, definitive dosimetric data are yet unavailable. According to the Society of Nuclear Medicine and Molecular Imaging, researchers are investigating the safety and efficacy of this radiotracer to meet Food and Drug Administration requirements. The aim of this study was to introduce the optimized procedure for 68Ga-DOTATOC preparation, using a novel germanium-68 (68Ge)/68Ga generator in Iran and evaluate the absorbed doses in numerous organs with high accuracy. Methods: The optimized conditions for preparing the radiolabeled complex were determined via several experiments by changing the ligand concentration, pH, temperature and incubation time. Radiochemical purity of the complex was assessed, using high-performance liquid chromatography and instant thin-layer chromatography. The absorbed dose of human organs was evaluated, based on biodistribution studies on Syrian rats via Radiation Absorbed Dose Assessment Resource Method. Results: 68Ga-DOTATOC was prepared with radiochemical purity of >98% and specific activity of 39.6 MBq/nmol. The complex demonstrated great stability at room temperature and in human serum at 37°C at least two hours after preparation. Significant uptake was observed in somatostatin receptor-positive tissues such as pancreatic and adrenal tissues (12.83 %ID/g and 0.91 %ID/g, respectively). Dose estimations in human organs showed that the pancreas, kidneys and adrenal glands received the maximum absorbed doses (0.105, 0.074 and 0.010 mGy/MBq, respectively). Also, the effective absorbed dose was estimated at 0.026 mSv/MBq for 68Ga-DOTATOC. Conclusion: The obtained results showed that 68Ga-DOTATOC can be considered as an effective agent for clinical PET imaging in Iran.
Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39(1):11-30.
Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29(2):147-57.
Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules. 2013;18(3):3379-409.
Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3] octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25(7):668-74.
Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992;43(1-3):27-35.
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439-47.
Van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599-606.
Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364-72.
Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(3 Suppl):S1-4.
Ö berg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966-73.
Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy. Chem Eur J. 1999;5(7):1974-81.
Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer. 2002;98(6):930-7.
Breeman WA, de Blois E, Chan HS, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41(4):314-21.
Sudbrock F, Fischer T, Zimmermanns B, Guliyev M, Dietlein M, Drzezga A, et al. Characterization of SnO2-based 68Ge/68Ga generators and 68Ga- DOTATATE preparations: radionuclide purity, radiochemical yield and long-term onstancy. EJNMMI Res. 2014;4(1):36.
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga- DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617-26.
Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET: a lesion-by-lesion analysis in patients. Ann Oncol. 2013; 24:13.
Mirzaei A, Jalilian AR, Aghanejad A, Mazidi M, Yousefnia H, Shabani G, et al. Preparation and evaluation of 68Ga-ECC as a PET renal imaging agent. Nucl Med Mol Imaging. 2015;49(3):208-16.
Aigner H, Bleise RA, Burns K, Campbell M, Currie LA, Danesi PR, et al. Quantifying uncertainty in nuclear analytical measurements. Vienna, Austria: International Atomaic Energy Agency; 2004.
Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Oak Ridge Asso Univ; 1999;2(2):705–16.
Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Asia Oceania J Nucl Med Biol. 2016; 4(1) Phys. 2003;85(3):294-310.
Yousefnia H, Zolghadri S, Jalilian AR, Tajik M, Ghannadi-Maragheh M. Preliminary dosimetric evaluation of 166Ho-TTHMP for human based on biodistribution data in rats. Appl Radiat Isot. 2014;94:260-5.
Brenner DJ. Effective dose: a flawed concept that could and should be replaced. Br J Radiol. 2008;81(967):521–3.
ICRP Publication 103. The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4):1-332.
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. Differential uptake of (68)Ga- DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res. 2013;194:353-71.
Luboldt W, Hartmann H, Wiedemann B, Zo¨phel K, Luboldt HJ. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTA PET/CT using the example of somatostatin receptor radionuclide therapy. Mol Imaging. 2010;9(6):351–8.
Velikyan I, Beyer GJ, Långström B. Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15(3):554-60.
Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48(10):1741-8.
Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A. Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application. Nucl Med Commun. 2010;31(8):753-8.
Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, et al. Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. Pancreas. 2013;42(6):937–43.
Soto-Montenegro ML, Peña-Zalbidea S, Mateos- Pérez JM, Oteo M, Romero E, Morcillo MA, et al. Meningiomas: a comparative study of 68Ga- DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014;9(11):e111624.
Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32(4):478-85.
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs). A service of the U.S. National Institutes of Health. Available at: URL: http://www.cancer.gov/clinicaltrials; 2015.
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines For PET/ CT tumour imaging with 68Ga-DOTAconjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004-10.
Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755-9.
Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol. 2008;10(6):341-8.
Palm S, Enmon RM Jr, Matei C, Kolbert KS, Xu S, Zanzonico PB et al. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90) Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44(7):1148-55.
ICRP Publication 62: Radiological Protection in Biomedical Research. 1st ed. Ottawa: ICRP Publication; 1993. P. 22.
Walker R, Smith G, Stabin M. First report of measured human dosimetry with 68Ga-DOTATATE. J Nucl Med. 2012;53(Supple 1):1514.
ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. Ottawa: ICRP Publication; 1988. P. 1-4.